CN Patent

CN107510651A — 一种小分子免疫药物的纳米靶向制剂制备及其用途

Assigned to Individual · Expires 2017-12-26 · 8y expired

What this patent protects

本发明涉及构建一种小分子免疫药物的纳米靶向制剂的方法及其用途。将目前无法解决水溶性问题，只能作为凝胶剂皮肤涂抹方式给药的巨大戟醇二萜醇当归酸酯及其衍生物，装载于载体辅料中，形成纳米级微粒，进而冻干形成粉针剂，不仅解决了其水溶性问题，同时提高了其活性成分的稳定性，尤其克服其由于疏水及毒性太大无法静脉给药或肿瘤介入方式给药的问题，扩展了其用途。

USPTO Abstract

本发明涉及构建一种小分子免疫药物的纳米靶向制剂的方法及其用途。将目前无法解决水溶性问题，只能作为凝胶剂皮肤涂抹方式给药的巨大戟醇二萜醇当归酸酯及其衍生物，装载于载体辅料中，形成纳米级微粒，进而冻干形成粉针剂，不仅解决了其水溶性问题，同时提高了其活性成分的稳定性，尤其克服其由于疏水及毒性太大无法静脉给药或肿瘤介入方式给药的问题，扩展了其用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN107510651A
Jurisdiction
CN
Classification
—
Expires
2017-12-26
Drug substance claim
No
Drug product claim
No
Assignee
Individual
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.